<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
<front>
<journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="publisher-id">10-PLCB-RA-1794R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1000796</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Computational Biology/Evolutionary Modeling</subject><subject>Computational Biology/Population Genetics</subject><subject>Computational Biology/Systems Biology</subject><subject>Ecology/Evolutionary Ecology</subject><subject>Evolutionary Biology/Microbial Evolution and Genomics</subject><subject>Infectious Diseases/Antimicrobials and Drug Resistance</subject><subject>Infectious Diseases/Bacterial Infections</subject><subject>Microbiology/Microbial Evolution and Genomics</subject><subject>Pharmacology/Drug Resistance</subject></subj-group></article-categories><title-group><article-title>Optimal Drug Synergy in Antimicrobial Treatments</article-title><alt-title alt-title-type="running-head">Optimal Antibiotic Synergy</alt-title></title-group><contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Torella</surname><given-names>Joseph Peter</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chait</surname><given-names>Remy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kishony</surname><given-names>Roy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, United States of America</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Physics, University of Oxford, Oxford, United Kingdom</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, United States of America</addr-line>       </aff><contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Bourne</surname><given-names>Philip E.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group><aff id="edit1">University of California San Diego, United States of America</aff><author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">roy_kishony@hms.harvard.edu</email></corresp>
<fn fn-type="con"><p>Conceived and designed the experiments: JPT RC RK. Performed the experiments: JPT. Analyzed the data: JPT RC RK. Wrote the paper: JPT RK.</p></fn>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="collection"><month>6</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>3</day><month>6</month><year>2010</year></pub-date><volume>6</volume><issue>6</issue><elocation-id>e1000796</elocation-id><history>
<date date-type="received"><day>11</day><month>2</month><year>2010</year></date>
<date date-type="accepted"><day>27</day><month>4</month><year>2010</year></date>
</history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2010</copyright-year><copyright-holder>Torella et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
<p>The rapid proliferation of antibiotic-resistant pathogens has spurred the use of drug combinations to maintain clinical efficacy and combat the evolution of resistance. Drug pairs can interact synergistically or antagonistically, yielding inhibitory effects larger or smaller than expected from the drugs' individual potencies. Clinical strategies often favor synergistic interactions because they maximize the rate at which the infection is cleared from an individual, but it is unclear how such interactions affect the evolution of multi-drug resistance. We used a mathematical model of <italic>in vivo</italic> infection dynamics to determine the optimal treatment strategy for preventing the evolution of multi-drug resistance. We found that synergy has two conflicting effects: it clears the infection faster and thereby decreases the time during which resistant mutants can arise, but increases the selective advantage of these mutants over wild-type cells. When competition for resources is weak, the former effect is dominant and greater synergy more effectively prevents multi-drug resistance. However, under conditions of strong resource competition, a tradeoff emerges in which greater synergy increases the rate of infection clearance, but also increases the risk of multi-drug resistance. This tradeoff breaks down at a critical level of drug interaction, above which greater synergy has no effect on infection clearance, but still increases the risk of multi-drug resistance. These results suggest that the optimal strategy for suppressing multi-drug resistance is not always to maximize synergy, and that in some cases drug antagonism, despite its weaker efficacy, may better suppress the evolution of multi-drug resistance.</p>
</abstract><abstract abstract-type="summary"><title>Author Summary</title>
<p>The use of antibiotics against bacterial infections has led to the emergence of multi-drug resistant pathogens such as tuberculosis and MRSA. In order to control resistance, clinicians have increasingly turned to multi-antibiotic therapies. The common wisdom is to use combinations of drugs that act synergistically to kill the infection, but the impact of drug synergy on the evolution of resistance is unclear. Using mathematical simulations of an <italic>in vivo</italic> infection model, we asked what level of drug synergy would minimize the risk of multi-drug resistance while preserving the efficacy of treatment. We found that synergy may increase or decrease the risk of multi-drug resistance in a given treatment, depending on infection properties such as mutation rate and the availability of resources. Surprisingly, under conditions of strong competition for resources within the host, we found that maximal synergy—currently favored in clinical settings—can actually increase the risk of multi-drug resistance. Our results identify conditions under which drug synergy exacerbates the problem of multi-drug resistance, and offer guidelines for the selection of drug pairs that suppress it.</p>
</abstract><funding-group><funding-statement>This work was supported in part by US National Institutes of Health grant R01 GM081617 (to RK) and a Herchel Smith Graduate Fellowship (to JPT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>As antibiotic-resistant pathogens become more common, clinicians increasingly turn to multi-drug treatment to control infection <xref ref-type="bibr" rid="pcbi.1000796-Levy1">[1]</xref>–<xref ref-type="bibr" rid="pcbi.1000796-Fitzgerald1">[5]</xref>. The inhibitory effect of two drugs in combination can be larger or smaller than expected from their individual effects, corresponding to synergistic or antagonistic interactions between the drugs respectively <xref ref-type="bibr" rid="pcbi.1000796-Loewe1">[6]</xref>–<xref ref-type="bibr" rid="pcbi.1000796-Keith1">[9]</xref>. Synergistic interactions are usually thought of as advantageous since, for a given amount of drug, they more effectively inhibit the growth of drug-sensitive pathogens. However, <italic>in vitro</italic> studies have suggested that, for the same level of inhibition, more synergistic drug pairs may foster antibiotic resistance <xref ref-type="bibr" rid="pcbi.1000796-Michel1">[10]</xref>–<xref ref-type="bibr" rid="pcbi.1000796-Klein1">[12]</xref>. Antagonistic drug combinations, on the other hand, are less effective at inhibiting drug-sensitive pathogens, but can reduce and even invert the selective advantage of single-drug resistant mutants, causing selection against resistance <xref ref-type="bibr" rid="pcbi.1000796-Chait1">[13]</xref>.</p>
<p>These recent observations point to a possible tradeoff in the choice of synergistic versus antagonistic drug combinations with respect to their effects on treating infection and suppressing antibiotic resistance. However, while antagonistic drug combinations increase selection against resistance, and should therefore minimize resistance, they also kill the infection more slowly, giving resistance more time to emerge. Antagonism therefore has two contradicting effects on the evolution of resistance: on one hand, it increases the risk of resistance by decreasing antibiotic inhibition and allowing more time for resistance to evolve; on the other hand, it decreases the risk of resistance by decreasing the selective advantage of single drug resistant mutants. We ask which of these opposing effects is stronger, and therefore which type of drug interaction – synergistic or antagonistic – best prevents the overall chance of emergence of multi-drug resistance.</p>
<p>We frame this problem in the context of a clinical infection, formalizing the two main factors in the success of an antibiotic treatment as “treatment efficacy” and “prevention of multi-drug resistance.” Treatment efficacy is the rate at which the infection is cleared by the treatment, and can be defined as the reciprocal of the time, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e001" xlink:type="simple"/></inline-formula>, at which the total infection is eliminated, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e002" xlink:type="simple"/></inline-formula>. Prevention of multi-drug resistance is defined as the reciprocal of the number of double-drug resistant mutants expected to arise during the course of treatment, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e003" xlink:type="simple"/></inline-formula>. In real infections, multi-drug resistance can arise either through a single mutation conferring cross-resistance to both drugs simultaneously, or through the sequential acquisition of mutations conferring resistance to each drug individually <xref ref-type="bibr" rid="pcbi.1000796-Michel1">[10]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Sanders1">[14]</xref>–<xref ref-type="bibr" rid="pcbi.1000796-Cohen1">[16]</xref>. Furthermore, resistance to a single drug can develop in several small steps or in one large step <xref ref-type="bibr" rid="pcbi.1000796-Mwangi1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Normark1">[17]</xref>–<xref ref-type="bibr" rid="pcbi.1000796-Handel1">[19]</xref>. For simplicity, and to emphasize the role of drug interactions, we concentrate here on an idealized case in which resistance to the two-drug combination evolves through sequential acquisition of two spontaneous mutations, each conferring strong resistance specific to one of the two antibiotics (<xref ref-type="fig" rid="pcbi-1000796-g001">Fig. 1</xref>).</p>
<fig id="pcbi-1000796-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000796.g001</object-id><label>Figure 1</label><caption>
<title>Model of the evolution of resistance in synergistic and antagonistic drug treatments.</title>
<p>(A) Graphical representation of model ODEs describing three bacterial subpopulations: the wild-type sensitive to both drugs (black, Eq. 1), single-drug resistant mutants (blue, Eq. 2), and double-drug resistant mutants (red, Eq. 3). Wild-type and single-drug resistant subpopulations grow with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e004" xlink:type="simple"/></inline-formula> (Eq. 4), mutate with rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e005" xlink:type="simple"/></inline-formula> and die with antibiotic killing rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e006" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e007" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e008" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e009" xlink:type="simple"/></inline-formula> are the effective drug doses they experience, respectively (Eq. 5). We do not model the growth of the double-drug resistant strain, but simply follow the number of such mutants expected to arise via mutation. (B) The wild-type, single-drug resistant and double-drug resistant mutants experience different effective doses, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e010" xlink:type="simple"/></inline-formula>, in the multi-drug treatment. The wild-type (black bars) is affected by both the drugs and their interaction, yielding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e011" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e012" xlink:type="simple"/></inline-formula> is the dose of each of the drugs A and B (we assume the two drugs are given at the same dose) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e013" xlink:type="simple"/></inline-formula> is the level of their interaction (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e014" xlink:type="simple"/></inline-formula>, synergistic; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e015" xlink:type="simple"/></inline-formula>, additive; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e016" xlink:type="simple"/></inline-formula>, antagonistic). We assume strong resistance, such that resistant mutants are completely unaffected by the drug to which they are resistant; the effective drug dose felt by the single-drug resistant mutant is therefore that of one of the drugs alone, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e017" xlink:type="simple"/></inline-formula>, and is independent of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e018" xlink:type="simple"/></inline-formula> (blue bars have a fixed value). Because double-drug resistant mutants are fully resistant to both antibiotics, they feel an effective dose of 0 (red bars). Increased synergy therefore increases killing of the wild-type, but also increases the selective advantage of the single-drug resistant mutants. Antagonistic drug pairs reduce this selective advantage, and can completely eliminate (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e019" xlink:type="simple"/></inline-formula>) or even invert it (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e020" xlink:type="simple"/></inline-formula>).</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.g001" xlink:type="simple"/></fig>
<p>We asked what level of drug interaction (ranging from strong synergy to strong antagonism) maximizes treatment efficacy (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e021" xlink:type="simple"/></inline-formula>) and prevention of multi-drug resistance (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e022" xlink:type="simple"/></inline-formula>). Maximizing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e023" xlink:type="simple"/></inline-formula> is straightforward: as more synergistic drug pairs have increased killing potency and clear the infection more quickly, maximally synergistic drug pairs should maximize <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e024" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1000796-Rybak1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Acar1">[20]</xref>. In attempting to maximize <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e025" xlink:type="simple"/></inline-formula>, however, the best choice of drug interaction is less clear. Assuming sequential acquisition of resistance to each drug, the rate at which multi-drug resistance arises will depend on the size of the single-drug resistant mutant population. The size of this single-mutant population, in turn, depends on two factors: the rate at which such mutants arise, and their selective advantage over the wild-type. Synergistic drug pairs decrease the first factor because they more quickly kill the source wild-type population from which single mutants arise. However, synergistic drug pairs also increase the second factor: single-drug resistant mutants will have a strong selective advantage in a synergistic treatment because resistance removes both the burden of one drug, and its enhancing effect on the other drug <xref ref-type="bibr" rid="pcbi.1000796-Chait1">[13]</xref> (<xref ref-type="fig" rid="pcbi-1000796-g001">Fig. 1B</xref>). Synergistic drug pairs therefore decrease the rate at which single-drug resistant mutants appear, but increase their selective advantage. Antagonistic drug pairs do the opposite: though they allow a larger number of single-drug resistant mutants to arise, they also diminish the selective advantage of these mutants. The net effect of a given drug interaction on the evolution of multi-drug resistance is therefore not obvious, and requires a quantitative model to determine the overall impact of mutation and selection's countervailing effects.</p>
<p>To better understand how drug interactions affect the risk of multi-drug resistance, we used a population genetic model of microbial infection previously applied to predict single-drug resistance <italic>in vivo</italic> in mice <xref ref-type="bibr" rid="pcbi.1000796-Jumbe1">[21]</xref>, and modified it to account for the sequential acquisition of mutations leading to multi-drug resistance. We used this model to ask what level of drug interaction maximizes treatment efficacy (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e026" xlink:type="simple"/></inline-formula>) and prevention of multi-drug resistance (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e027" xlink:type="simple"/></inline-formula>).</p>
</sec><sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Simple model for the evolution of resistance in multi-drug treatment</title>
<p>We based our model on work by Jumbe <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1000796-Jumbe1">[21]</xref>, which investigated a mouse-thigh <italic>P. aeruginosa</italic> infection model <xref ref-type="bibr" rid="pcbi.1000796-Craig1">[22]</xref>–<xref ref-type="bibr" rid="pcbi.1000796-Eagle1">[24]</xref> and provided a mathematical model that quantitatively described the relationship between exposure to the fluoroquinolone antibiotic levofloxacin, and changes in drug-susceptible and drug-resistant bacterial subpopulations over time. This mathematical model was successful both in reproducing the observed changes in drug-susceptible and –resistant subpopulations over time, and in predicting the dose of levofloxacin needed to suppress amplification of levofloxacin-resistant (efflux-pump-expressing) mutants. To investigate the effect of antibiotic interactions on treatment efficacy and the prevention of multi-drug resistance in a simple scenario, we modified the Jumbe <italic>et al.</italic> model in four ways: we include a second antibiotic in our model; we assume a constant antibiotic dose; we assume a low hill coefficient, consistent with the mechanisms of a range of antibiotics <xref ref-type="bibr" rid="pcbi.1000796-Regoes1">[25]</xref>; and we assume no cost for antibiotic resistance. The consequences of these assumptions are discussed throughout the text.</p>
<p>Our model incorporates treatment with two antibiotics, A and B. It uses a set of ordinary differential equations (ODEs) to follow the population sizes of the drug-sensitive wild-type strain (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e028" xlink:type="simple"/></inline-formula>), the total single-drug resistant population (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e029" xlink:type="simple"/></inline-formula>; we assume symmetry between drugs A and B such that their respective resistant populations are equal, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e030" xlink:type="simple"/></inline-formula>), and the expected number of multi-drug resistant mutants (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e031" xlink:type="simple"/></inline-formula>) arising over time (<xref ref-type="fig" rid="pcbi-1000796-g001">Fig. 1A</xref>; <xref ref-type="sec" rid="s4">Methods</xref>):<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e032" xlink:type="simple"/><label>(1)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e033" xlink:type="simple"/><label>(2)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e034" xlink:type="simple"/><label>(3)</label></disp-formula>Populations are affected by growth, antibiotic killing and mutation, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e035" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e036" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e037" xlink:type="simple"/></inline-formula> are the growth rate, antibiotic killing rate and frequency of resistance mutations per generation, respectively, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e038" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e039" xlink:type="simple"/></inline-formula> are the effective doses of antibiotic felt by the wild-type and single-drug resistant mutant populations. We assume for simplicity that antibiotic resistance imposes no fitness cost, so that the growth rates of the sensitive and resistant populations are the same. To account for competition for resources, we assume this growth rate is given by the logistic equation,<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e040" xlink:type="simple"/><label>(4)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e041" xlink:type="simple"/></inline-formula> is the maximal growth rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e042" xlink:type="simple"/></inline-formula> is the total population size, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e043" xlink:type="simple"/></inline-formula> is the maximal carrying capacity (<xref ref-type="supplementary-material" rid="pcbi.1000796.s001">Fig. S1B</xref>). This competition for resources was included in the <italic>in vivo</italic> murine infection model <xref ref-type="bibr" rid="pcbi.1000796-Jumbe1">[21]</xref>, and has been observed in or inferred from a range of infections <xref ref-type="bibr" rid="pcbi.1000796-Smith1">[26]</xref>, including <italic>S. pneumoniae</italic> <xref ref-type="bibr" rid="pcbi.1000796-Lipsitch1">[27]</xref>, and Methicillin-Resistant <italic>S. aureus</italic> (MRSA) <xref ref-type="bibr" rid="pcbi.1000796-DallAntonia1">[28]</xref>.</p>
<p>While we assume the growth rates of the wild-type and single-drug resistant mutants are the same, the rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e044" xlink:type="simple"/></inline-formula> at which they are killed by antibiotic are different and depend on the effective antibiotic dose, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e045" xlink:type="simple"/></inline-formula>, felt by each population:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e046" xlink:type="simple"/><label>(5)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e047" xlink:type="simple"/></inline-formula> is the maximal killing rate and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e048" xlink:type="simple"/></inline-formula> is the Hill coefficient, which determines the steepness of the killing rate as a function of drug dose. In contrast to Jumbe <italic>et al.</italic>, we set <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e049" xlink:type="simple"/></inline-formula>, which is representative of many common antibiotics <xref ref-type="bibr" rid="pcbi.1000796-Regoes1">[25]</xref>, although different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e050" xlink:type="simple"/></inline-formula> give rise to similar overall model behavior (<xref ref-type="supplementary-material" rid="pcbi.1000796.s002">Fig. S2</xref>). The effective drug dose, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e051" xlink:type="simple"/></inline-formula>, depends on the dosage of the two drugs and on their interaction (<xref ref-type="fig" rid="pcbi-1000796-g001">Fig. 1B</xref>, <xref ref-type="supplementary-material" rid="pcbi.1000796.s006">Text S1</xref>, <xref ref-type="supplementary-material" rid="pcbi.1000796.s001">Fig. S1A</xref>). For simplicity we assume both drugs are administered at the same dose, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e052" xlink:type="simple"/></inline-formula>, defined in units of their minimum inhibitory concentration (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e053" xlink:type="simple"/></inline-formula>), the single-drug dose at which the wild-type death rate equals its growth rate at resource-unlimited conditions: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e054" xlink:type="simple"/></inline-formula>. For the wild-type, the effective dose is the sum of the dosage of the two drugs plus their level of interaction <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e055" xlink:type="simple"/></inline-formula>: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e056" xlink:type="simple"/></inline-formula>. Values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e057" xlink:type="simple"/></inline-formula> are positive, zero, or negative for synergy, additivity and antagonism, respectively. While in practice the value of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e058" xlink:type="simple"/></inline-formula> is specific to a given drug pair <xref ref-type="bibr" rid="pcbi.1000796-Yeh1">[29]</xref>, we treat it as continuous in order to investigate all potential treatment strategies. We assume that single-drug resistant mutants are affected by only one of the drugs, which is reasonable in the case of resistance mechanisms that decrease the intracellular concentration of antibiotic, such as efflux pump expression or enzymatic degradation <xref ref-type="bibr" rid="pcbi.1000796-Hegreness1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Chait1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Yeh2">[30]</xref>. The effective dose of single-drug resistant mutants is therefore <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e059" xlink:type="simple"/></inline-formula>, and is independent of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e060" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g001">Fig. 1B</xref>). Except where indicated, we set <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e061" xlink:type="simple"/></inline-formula> (general model behavior is robust to changes in drug dosage, <xref ref-type="supplementary-material" rid="pcbi.1000796.s002">Fig. S2A</xref>), which for an additive drug pair is consistent with the drug dosage used in Jumbe <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1000796-Jumbe1">[21]</xref>.</p>
<p>Mutations from wild-type to single-drug resistance, or from single- to double-drug resistance, arise at a rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e062" xlink:type="simple"/></inline-formula> per individual per replication, or <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e063" xlink:type="simple"/></inline-formula> per individual per unit time. Since in any effective treatment the number of double mutants arising is smaller than 1, we do not account for the growth or death of this fractional population, but rather define <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e064" xlink:type="simple"/></inline-formula> as the integrated number of double mutants generated via mutation during treatment (Eq. 3). Prevention of multi-drug resistance is then defined as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e065" xlink:type="simple"/></inline-formula>.</p>
<p>The model therefore consists of Eqs. 1–5. Parameter values, following Jumbe <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1000796-Jumbe1">[21]</xref>, are given in <xref ref-type="supplementary-material" rid="pcbi.1000796.s005">Table S1</xref>. Initial conditions for the model are <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e066" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e067" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e068" xlink:type="simple"/></inline-formula> - the population sizes at the onset of treatment. We assume that prior to treatment, the infections have grown from a single cell to the initial population size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e069" xlink:type="simple"/></inline-formula> while mutating; while the overall mutation rate is a function of model parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e070" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e071" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e072" xlink:type="simple"/></inline-formula> (Eqs. 2, 3), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e073" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e074" xlink:type="simple"/></inline-formula> are functions of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e075" xlink:type="simple"/></inline-formula> alone: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e076" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e077" xlink:type="simple"/></inline-formula>. No double-drug resistant mutants are present: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e078" xlink:type="simple"/></inline-formula>. We integrate the ODEs with these initial conditions (<xref ref-type="sec" rid="s4">Methods</xref>) and define <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e079" xlink:type="simple"/></inline-formula> as the time at which the total population size drops below one (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e080" xlink:type="simple"/></inline-formula> is defined as infinity if the population reaches a non-zero steady state).</p>
</sec><sec id="s2b">
<title>Antibiotic interactions create a saturable tradeoff between treatment efficacy and prevention of multi-drug resistance</title>
<p>To determine the impact of drug interaction on treatment outcome, we first looked at the differences in treatment efficacy (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e081" xlink:type="simple"/></inline-formula>) and prevention of multi-drug resistance (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e082" xlink:type="simple"/></inline-formula>) over a range of drug interaction values (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e083" xlink:type="simple"/></inline-formula>) while holding drug dosage fixed (<xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e084" xlink:type="simple"/></inline-formula>). We observed two distinct and robust (<xref ref-type="supplementary-material" rid="pcbi.1000796.s002">Fig. S2</xref>) behaviors, depending on whether <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e085" xlink:type="simple"/></inline-formula> falls above or below a critical value, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e086" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>; for the parameters used, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e087" xlink:type="simple"/></inline-formula>).</p>
<fig id="pcbi-1000796-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000796.g002</object-id><label>Figure 2</label><caption>
<title>Choice of drug interaction presents a tradeoff between treatment efficacy and prevention of multi-drug resistance.</title>
<p>Below a critical level of drug interaction (unshaded region, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e088" xlink:type="simple"/></inline-formula>), treatment efficacy (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e089" xlink:type="simple"/></inline-formula>, blue) and prevention of multi-drug resistance (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e090" xlink:type="simple"/></inline-formula>, black) exhibit a tradeoff: increased synergy yields higher efficacy, but at the expense of lower resistance prevention. Above <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e091" xlink:type="simple"/></inline-formula>, however, efficacy plateaus: increasing synergy beyond this ‘synergy ceiling’ fails to improve treatment efficacy, but continues to diminish resistance prevention (shaded region, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e092" xlink:type="simple"/></inline-formula>).</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.g002" xlink:type="simple"/></fig>
<p>For <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e093" xlink:type="simple"/></inline-formula>, we observed a tradeoff between treatment efficacy and prevention of resistance. In this regime, increasing synergy yields greater <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e094" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>, unshaded region); this is expected, as increasing the synergistic interaction between the drugs kills the wild-type more quickly. Despite faster infection clearance, however, greater synergy actually decreases <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e095" xlink:type="simple"/></inline-formula>; namely, it increases the risk of multi-drug resistance. Conversely, more antagonistic drug pairs increase <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e096" xlink:type="simple"/></inline-formula>, albeit at the expense of reduced efficacy.</p>
<p>This tradeoff between efficacy and prevention of resistance breaks down at a critical threshold, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e097" xlink:type="simple"/></inline-formula>, above which increasing synergy no longer increases <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e098" xlink:type="simple"/></inline-formula>, but still decreases <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e099" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>, shaded region). Above this “synergy ceiling,” further increasing synergy therefore has only undesirable effects, since it increases the risk of multi-drug resistance without increasing efficacy. Optimal drug pairs for treating the given infection must therefore have a level of drug interaction lower than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e100" xlink:type="simple"/></inline-formula> and, due to the tradeoff between <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e101" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e102" xlink:type="simple"/></inline-formula>, the optimal value of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e103" xlink:type="simple"/></inline-formula> will depend on the relative importance assigned to these two conflicting goals.</p>
</sec><sec id="s2c">
<title>The frequency of resistance mutations determines the “synergy ceiling” <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e104" xlink:type="simple"/></inline-formula></title>
<p>To understand what determines the level of the synergy ceiling, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e105" xlink:type="simple"/></inline-formula>, we asked what causes the transition from tradeoff behavior at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e106" xlink:type="simple"/></inline-formula>, to plateau behavior at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e107" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>). Due to the sharp biphasic behavior of efficacy (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e108" xlink:type="simple"/></inline-formula>) around <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e109" xlink:type="simple"/></inline-formula>, we looked to population time courses to determine how the time of clearance, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e110" xlink:type="simple"/></inline-formula>, was affected by drug interactions below, at or above <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e111" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e112" xlink:type="simple"/></inline-formula>, respectively; <xref ref-type="fig" rid="pcbi-1000796-g003">Fig. 3A</xref>). For <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e113" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g003">Fig. 3A</xref>, top), the wild-type subpopulation outlives the single-drug resistant mutants and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e114" xlink:type="simple"/></inline-formula>. Since wild-type killing is stronger for more synergistic drug pairs, increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e115" xlink:type="simple"/></inline-formula> decreases <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e116" xlink:type="simple"/></inline-formula>, explaining why efficacy increases with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e117" xlink:type="simple"/></inline-formula> in this region (<xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>, unshaded region). For <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e118" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g003">Fig. 3A</xref>; bottom), however, the wild-type is eliminated before the single-mutant population, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e119" xlink:type="simple"/></inline-formula>. Because the killing rate of the single-drug resistant mutants is independent of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e120" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e121" xlink:type="simple"/></inline-formula> is effectively independent of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e122" xlink:type="simple"/></inline-formula>, causing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e123" xlink:type="simple"/></inline-formula> to plateau for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e124" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>, shaded region). <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e125" xlink:type="simple"/></inline-formula> is therefore the level of drug interaction for which wild-type and single-mutant populations are cleared simultaneously (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e126" xlink:type="simple"/></inline-formula>; <xref ref-type="fig" rid="pcbi-1000796-g003">Fig. 3A</xref>, middle).</p>
<fig id="pcbi-1000796-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000796.g003</object-id><label>Figure 3</label><caption>
<title>The synergy ceiling <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e127" xlink:type="simple"/></inline-formula> is determined by clearance of the wild-type population before the single-mutant subpopulation.</title>
<p>(A) Population sizes of the wild-type (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e128" xlink:type="simple"/></inline-formula>, black) and single-drug resistant mutants (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e129" xlink:type="simple"/></inline-formula>, blue) over treatment courses with levels of interaction below, at or above the critical value <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e130" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e131" xlink:type="simple"/></inline-formula>). Populations start with sizes <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e132" xlink:type="simple"/></inline-formula> and are killed by antibiotics until they are cleared at times <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e133" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e134" xlink:type="simple"/></inline-formula> respectively; the overall time of clearance of the infection is simply <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e135" xlink:type="simple"/></inline-formula> (orange markers). The interaction level <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e136" xlink:type="simple"/></inline-formula> affects the order in which the wild-type and the single-drug resistant subpopulations are eliminated: below the synergy ceiling (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e137" xlink:type="simple"/></inline-formula>, top), the wild-type is eliminated after the single-drug resistant mutant and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e138" xlink:type="simple"/></inline-formula>; at the synergy ceiling (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e139" xlink:type="simple"/></inline-formula>, middle), the two populations die simultaneously and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e140" xlink:type="simple"/></inline-formula>; above the synergy ceiling (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e141" xlink:type="simple"/></inline-formula>, bottom), the single-drug resistant mutant outlives the wild-type, such that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e142" xlink:type="simple"/></inline-formula>. Because increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e143" xlink:type="simple"/></inline-formula> increases the wild-type killing rate but has no effect on the single-mutant killing rate, efficacy increases with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e144" xlink:type="simple"/></inline-formula> below the synergy ceiling (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e145" xlink:type="simple"/></inline-formula>), but plateaus at and above it (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e146" xlink:type="simple"/></inline-formula>; vertical dashed line: notice that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e147" xlink:type="simple"/></inline-formula> is the same both at and above the synergy ceiling). (B) Increased mutation rates, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e148" xlink:type="simple"/></inline-formula>, give rise to lower <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e149" xlink:type="simple"/></inline-formula>. Inset: treatment efficacy, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e150" xlink:type="simple"/></inline-formula>, plateaus at lower levels of drug interaction <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e151" xlink:type="simple"/></inline-formula> for higher mutation rates (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e152" xlink:type="simple"/></inline-formula>, blue; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e153" xlink:type="simple"/></inline-formula>, orange; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e154" xlink:type="simple"/></inline-formula>, green; blue and green lines are shifted slightly along y-axis for clarity); <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e155" xlink:type="simple"/></inline-formula> values for each line are indicated by vertical dashed lines, and by circles in the main panel. Orange markers indicate the treatment efficacy achieved for different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e156" xlink:type="simple"/></inline-formula> when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e157" xlink:type="simple"/></inline-formula>, corresponding to the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e158" xlink:type="simple"/></inline-formula> values in panel A.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.g003" xlink:type="simple"/></fig>
<p>Since <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e159" xlink:type="simple"/></inline-formula> represents the level of drug interaction for which <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e160" xlink:type="simple"/></inline-formula>, parameters that differentially alter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e161" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e162" xlink:type="simple"/></inline-formula> will alter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e163" xlink:type="simple"/></inline-formula>. While we found that a number of model parameters had some effect on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e164" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1000796.s002">Fig. S2</xref>), the strongest effect was due to changes in the frequency of resistance mutations, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e165" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e166" xlink:type="simple"/></inline-formula> differentially affects <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e167" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e168" xlink:type="simple"/></inline-formula> because, although it has virtually no effect on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e169" xlink:type="simple"/></inline-formula>, the single-mutant population size at the onset of treatment increases linearly with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e170" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e171" xlink:type="simple"/></inline-formula>, thereby increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e172" xlink:type="simple"/></inline-formula>. For <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e173" xlink:type="simple"/></inline-formula> to match this increase in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e174" xlink:type="simple"/></inline-formula>, the wild-type killing rate must decrease; namely, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e175" xlink:type="simple"/></inline-formula> must be reduced. We therefore expected <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e176" xlink:type="simple"/></inline-formula> to decrease with increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e177" xlink:type="simple"/></inline-formula> and, indeed, increasing the frequency of resistance mutations gave rise to consistent decreases in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e178" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g003">Fig. 3B</xref>). Interestingly, for high frequencies of resistance (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e179" xlink:type="simple"/></inline-formula>) the synergy ceiling <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e180" xlink:type="simple"/></inline-formula> falls below zero (representing an antagonistic drug interaction); in this case mildly synergistic and even additive interactions fall in the undesirable regime where the risk of multi-drug resistance increases without any corresponding gain in treatment efficacy.</p>
</sec><sec id="s2d">
<title>Competition for resources underlies the tradeoff between treatment efficacy and prevention of multi-drug resistance</title>
<p>Why does synergy, despite clearing the infection faster, increase the risk of multi-drug resistance (<xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>)? Since synergistic drug pairs clear the infection more quickly than antagonistic drug pairs, the rate at which they generate double mutants must also be higher. The overall rate at which double mutants arise, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e181" xlink:type="simple"/></inline-formula> (Eqs. 3, 4), is affected by two variables: it increases with the size of the single-mutant population, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e182" xlink:type="simple"/></inline-formula>, and decreases with total population size, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e183" xlink:type="simple"/></inline-formula>, due to the inhibitory effect of resource limitation on growth and mutation (<xref ref-type="fig" rid="pcbi-1000796-g004">Fig. 4A</xref>). The total number of double mutants expected to arise is simply the integral of this instantaneous rate over the treatment course. In order to determine why synergistic treatments increase <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e184" xlink:type="simple"/></inline-formula>, we therefore analyzed the trajectories of synergistic and antagonistic treatments through the space of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e185" xlink:type="simple"/></inline-formula> versus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e186" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g004">Fig. 4A</xref>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e187" xlink:type="simple"/></inline-formula>, solid line, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e188" xlink:type="simple"/></inline-formula>, dashed line). The initial slopes of these trajectories (<xref ref-type="fig" rid="pcbi-1000796-g004">Fig. 4A</xref>, arrows) are determined by the relative fitness of the wild-type and single-drug resistant populations under antibiotic treatment. The synergistic treatment selects strongly against the wild-type population, producing a trajectory with a steep slope that drives treatment into a region of high <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e189" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g004">Fig. 4A</xref>, red region); this is because the rapid decrease in wild-type population size relieves competition for resources, creating a window of opportunity in which the still-large single-mutant population can rapidly grow and mutate. Conversely, the antagonistic treatment selects only weakly against the wild-type, producing a trajectory with a shallow slope that skirts the high <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e190" xlink:type="simple"/></inline-formula> region. Antagonistic drug pairs therefore decrease <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e191" xlink:type="simple"/></inline-formula> in a competition-dependent fashion: weak killing of the wild-type maintains competition for resources, limiting growth and mutation of the single-drug resistant population until it is eliminated.</p>
<fig id="pcbi-1000796-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000796.g004</object-id><label>Figure 4</label><caption>
<title>Prevention of multi-drug resistance by drug antagonism depends on resource competition.</title>
<p>(A) Heat map of instantaneous rates of double-mutant formation, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e192" xlink:type="simple"/></inline-formula>, as a function of single-mutant and total population sizes: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e193" xlink:type="simple"/></inline-formula> increases with the size of the single-mutant population, and decreases with total population size due to resource competition. Treatment course trajectories for synergistic (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e194" xlink:type="simple"/></inline-formula>, solid line) and antagonistic (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e195" xlink:type="simple"/></inline-formula>, dashed line) drug treatments begin with total initial population size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e196" xlink:type="simple"/></inline-formula> and initial single-mutant population size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e197" xlink:type="simple"/></inline-formula> (magenta circle), and move toward the origin as the infection is cleared (black circles indicate 20-minute intervals). The different initial slopes of these trajectories (arrows), determined by the relative fitness of the wild-type and single-drug resistant mutants in synergistic versus antagonistic treatments, lead them to different regions of the heat map: synergistic drug pairs quickly kill the wild-type, relieving resource competition before the single-mutant population is killed and leading to a region with high <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e198" xlink:type="simple"/></inline-formula> (solid trajectory goes through red region), while antagonistic pairs kill the single mutants before competition is relieved, leading to a region of low <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e199" xlink:type="simple"/></inline-formula> (dashed trajectory goes through green region). (B) The <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e200" xlink:type="simple"/></inline-formula> over each treatment plotted as a function of time; black circles indicate 40-minute intervals in this panel. (C) Relative ability of these strongly synergistic and antagonistic drug pairs to prevent multi-drug resistance, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e201" xlink:type="simple"/></inline-formula>, for different initial population sizes (circles). For strong resource competition at the start of treatment (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e202" xlink:type="simple"/></inline-formula> close to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e203" xlink:type="simple"/></inline-formula>), antagonistic drug pairs prevent resistance better than synergistic drug pairs (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e204" xlink:type="simple"/></inline-formula>). For weak competition, however (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e205" xlink:type="simple"/></inline-formula> significantly less than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e206" xlink:type="simple"/></inline-formula>), synergistic drug pairs better prevent resistance (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e207" xlink:type="simple"/></inline-formula>). Artificially turning off wild-type to single-drug resistant mutation during treatment (leaving only the single-mutant population that exists at the onset of treatment) eliminates the advantage of synergy over antagonism at low <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e208" xlink:type="simple"/></inline-formula> (triangles). (D) When initial population size is low and synergy is advantageous, the tradeoff between treatment efficacy and prevention of multi-drug resistance is eliminated, such that maximally synergistic drug pairs yield both the greatest treatment efficacy and greatest prevention of multi-drug resistance (compare panel C to <xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>).</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.g004" xlink:type="simple"/></fig>
<p>It is important to note that resource competition is significant only at the beginning of treatment, when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e209" xlink:type="simple"/></inline-formula>. If competition for resources is required for the advantage of antagonism over synergy in preventing resistance, then we should expect a decrease in initial population size to decrease this advantage. To test this prediction, we looked at the relative ability of our representative synergistic (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e210" xlink:type="simple"/></inline-formula>) and antagonistic (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e211" xlink:type="simple"/></inline-formula>) drug pairs to prevent multi-drug resistance, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e212" xlink:type="simple"/></inline-formula>, over a range of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e213" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g004">Fig. 4C</xref>, circles; sensitivity to other model parameters is minimal, <xref ref-type="supplementary-material" rid="pcbi.1000796.s002">Fig. S2</xref>). Indeed, we found that the advantage of antagonistic drug pairs in preventing resistance (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e214" xlink:type="simple"/></inline-formula>, below dashed line) was limited to cases where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e215" xlink:type="simple"/></inline-formula> is close to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e216" xlink:type="simple"/></inline-formula>. In fact, for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e217" xlink:type="simple"/></inline-formula> significantly lower than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e218" xlink:type="simple"/></inline-formula>, the trend reverses and synergy better prevents resistance (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e219" xlink:type="simple"/></inline-formula>, above dashed line). This is because, for low population sizes, resource competition effects are negligible; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e220" xlink:type="simple"/></inline-formula> therefore no longer depends on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e221" xlink:type="simple"/></inline-formula>, and becomes a function of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e222" xlink:type="simple"/></inline-formula> alone. Because synergistic drug pairs better limit <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e223" xlink:type="simple"/></inline-formula> by quickly killing the wild-type population from which single mutants arise, they therefore also better limit multi-drug resistance in cases of weak competition. Indeed, this advantage of synergy disappeared entirely when we artificially turned off wild-type to single-mutant mutation, allowing only those single mutants present at the start of treatment to contribute to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e224" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g004">Fig. 4C</xref>, triangles).</p>
<p>Importantly, when competition for resources is weak (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e225" xlink:type="simple"/></inline-formula> significantly less than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e226" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e227" xlink:type="simple"/></inline-formula>), the tradeoff between treatment efficacy and prevention of multi-drug resistance no longer exists (<xref ref-type="fig" rid="pcbi-1000796-g004">Fig. 4D</xref>; compare with <xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>). As a result, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e228" xlink:type="simple"/></inline-formula> is no longer useful as a “synergy ceiling” because, although drug pairs with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e229" xlink:type="simple"/></inline-formula> do not further improve <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e230" xlink:type="simple"/></inline-formula>, they do improve <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e231" xlink:type="simple"/></inline-formula>. For infections with weak competition, the use of maximally synergistic drug pairs therefore represents the best possible treatment strategy.</p>
</sec></sec><sec id="s3">
<title>Discussion</title>
<p>We used a population dynamic model of bacterial infection to determine what drug interactions best suppress the emergence of multi-drug resistance. Whereas antagonistic drug pairs kill bacterial populations more slowly, and therefore allow more time for resistance to emerge, they also decrease the selective advantage of resistant mutants. Which of these two opposing effects of antagonism dominates in determining its overall impact on the chance of evolving multi-drug resistance? Framing this problem in the context of a clinical infection, we asked how two measures of treatment outcome, treatment efficacy and prevention of multi-drug resistance, depend on drug interaction.</p>
<p>We found that the optimal drug interaction can be determined primarily as a function of two infection parameters: population size at the outset of treatment, and the frequency of resistance mutations (see summary of our results in <xref ref-type="supplementary-material" rid="pcbi.1000796.s003">Fig. S3</xref>). For clinically relevant scenarios where initial population sizes are well below the carrying capacity, competition for resources is weak and synergy, which is typically preferred in clinical settings for its superior treatment efficacy <xref ref-type="bibr" rid="pcbi.1000796-Pillai1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Rybak1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Acar1">[20]</xref>, is also expected to best prevent the emergence of multi-drug resistance.</p>
<p>Where resource competition is significant, however, strong synergy may not always be the optimal treatment strategy. Real infections frequently exhibit competition, due either to a scarcity of carbon or iron <xref ref-type="bibr" rid="pcbi.1000796-Smith1">[26]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Freter1">[31]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Weinberg1">[32]</xref>, or saturation of available adhesion sites (e.g. in biofilm formation <xref ref-type="bibr" rid="pcbi.1000796-Nadell1">[33]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Zhang1">[34]</xref>). In our model, such competition is predicted to give rise to a tradeoff between treatment efficacy and resistance prevention: increased synergy leads to greater efficacy, but at the expense of an increased risk of multi-drug resistance. Importantly, this tradeoff saturates for levels of synergy greater than a critical value <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e232" xlink:type="simple"/></inline-formula>, above which greater synergy does not further increase efficacy, but still increases the risk of multi-drug resistance. If the goal is to minimize multi-drug resistance, then choosing drug interactions above this “synergy ceiling” may be counterproductive. This is especially important given the dependence of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e233" xlink:type="simple"/></inline-formula> on the frequency of resistance mutations: our model predicts that for infections where resistance rates are high (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e234" xlink:type="simple"/></inline-formula>) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e235" xlink:type="simple"/></inline-formula> may be negative (antagonistic), favoring the use of antagonistic drug pairs over mildly synergistic or even purely additive antibiotic combinations. Indeed, for the modified Jumbe <italic>et al.</italic> model that we study, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e236" xlink:type="simple"/></inline-formula> is nearly additive; and while the resistance frequency we use may be an overestimate (Jumbe <italic>et al.</italic> determined this as the rate of all mutations conferring only a 3-fold increase in the MIC), these and higher mutation rates have been identified in human pathogens <xref ref-type="bibr" rid="pcbi.1000796-Martinez1">[35]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Tucker1">[36]</xref>. Together, the potential for strong competition and high mutation rates in infection suggest that the tradeoff and synergy ceiling behaviors observed in our model – as well as the ability of antagonistic drug pairs to minimize multi-drug resistance – may describe the properties of some clinical infections.</p>
<p>We emphasize that drawing concrete therapeutic conclusions from this study would be beyond its scope. Our model incorporates many simplifying assumptions: we assume <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e237" xlink:type="simple"/></inline-formula> to be a fixed value, although it has been observed to change with both the absolute and relative doses of the antibiotics administered <xref ref-type="bibr" rid="pcbi.1000796-Meletiadis1">[37]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Rand1">[38]</xref>; drug administration and pharmacokinetics are not considered, although they may significantly impact the evolution of resistance <xref ref-type="bibr" rid="pcbi.1000796-Craig2">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Lipsitch2">[39]</xref>–<xref ref-type="bibr" rid="pcbi.1000796-Foo1">[42]</xref>; resistance mutation rates per generation are assumed to be independent of growth and antibiotic-killing rates; and while we consider an idealized case in which multi-drug resistance arises from strong, sequential mutations conferring resistance to each antibiotic, real mutations may confer cross-resistance to both drugs simultaneously, or only partial resistance to a single drug <xref ref-type="bibr" rid="pcbi.1000796-Michel1">[10]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Sanders1">[14]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Cohen1">[16]</xref>. One consequence of partial resistance is antibiotic killing of drug-resistant mutants for drug interactions above <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e238" xlink:type="simple"/></inline-formula>; while for strong resistance this killing would be minimal, weak resistance may allow enough killing to undermine synergy ceiling behavior (<xref ref-type="supplementary-material" rid="pcbi.1000796.s004">Fig. S4</xref>). Finally, we note that this model does not consider the impact of host immune defenses, which may substantially impact microbial growth and death rates in clinical infections <xref ref-type="bibr" rid="pcbi.1000796-Grant1">[43]</xref>, <xref ref-type="bibr" rid="pcbi.1000796-Wodarz1">[44]</xref>; whether the influence of host defenses favors the use of some drug combinations over others, however, remains to be seen.</p>
<p>While these caveats indicate the limitations of this simple model and suggest important avenues for future study, our results make a number of novel predictions about the relationship between drug interaction and multi-drug resistance: that there exist conditions under which antagonistic drug pairs may better prevent multi-drug resistance despite their weaker efficacy; that there is a synergy ceiling to how much efficacy can be achieved by modulating drug interaction; and that, below this ceiling, changes in drug interaction may produce a tradeoff between inhibition and multi-drug resistance. By basing our model on a previous experimental model of infection <xref ref-type="bibr" rid="pcbi.1000796-Jumbe1">[21]</xref>, we have identified regions of parameter space in which such behaviors may be relevant in a clinical scenario, and which could be tested in future experimental models of infection. Finally, our model highlights the idea that the optimal choice of drug pair in treating an infection may be contextual: while strongly synergistic drug pairs seem the preferred strategy in scenarios where resource limitation and other forms of competition are negligible, antagonistic drug pairs may best prevent resistance in cases of high mutation rates and strong intra-infection competition. While present therapeutic knowledge generally favors synergistic drug pairs, our work motivates further research into the impact and potential utility of antagonistic interactions both in clinical and in ecological settings.</p>
</sec><sec id="s4" sec-type="methods">
<title>Methods</title>
<sec id="s4a">
<title>Model details</title>
<p>Our model consists of 3 ODEs (Eq. 1–3) describing the population sizes of the wild-type and single-drug resistant mutants (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e239" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e240" xlink:type="simple"/></inline-formula>), as well as the number of double mutants expected to arise during a treatment course (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e241" xlink:type="simple"/></inline-formula>). Parameter values for this model include first-order maximal growth (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e242" xlink:type="simple"/></inline-formula>) and death rate (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e243" xlink:type="simple"/></inline-formula>) constants, carrying capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e244" xlink:type="simple"/></inline-formula> and mutation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e245" xlink:type="simple"/></inline-formula> (per individual per generation), which were taken from the <italic>in vivo</italic> murine model investigated in Jumbe <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1000796-Jumbe1">[21]</xref> (<xref ref-type="supplementary-material" rid="pcbi.1000796.s005">Table S1</xref>). Initial population sizes (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e246" xlink:type="simple"/></inline-formula>) were determined by assuming that, prior to treatment, the infections grew from a single cell to the initial population size <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e247" xlink:type="simple"/></inline-formula> while mutating, such that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e248" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e249" xlink:type="simple"/></inline-formula>; unless otherwise indicated, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e250" xlink:type="simple"/></inline-formula>. ODEs were solved in MATLAB (Version 7.1, MathWorks, Natick, MA) using a built-in, numerical ODE solver (ODE45). To avoid artifacts associated with using continuous ODEs to describe finite populations, each step was modified with the assumption that the wild-type or single-drug resistant population is eliminated (size decreases to zero) if its size drops below one.</p>
</sec></sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pcbi.1000796.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.s001" xlink:type="simple"><label>Figure S1</label><caption>
<p>Models of drug interaction and logistic growth. (A) Model of drug interaction. The effective drug dose for the wild-type strain, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e251" xlink:type="simple"/></inline-formula>, is a function of three variables: the doses of drugs A and B (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e252" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e253" xlink:type="simple"/></inline-formula>) and the interaction parameter <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e254" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1000796.s006">Text S1</xref>). Isoboles of the wild-type effective dose (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e255" xlink:type="simple"/></inline-formula>), are shown for additive (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e256" xlink:type="simple"/></inline-formula>, black), synergistic (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e257" xlink:type="simple"/></inline-formula>, red) and antagonistic (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e258" xlink:type="simple"/></inline-formula>, blue) drug pairs. While for additive drug pairs the effective dose is a simple sum of the drugs' individual doses, synergistic or antagonistic drug pairs achieve the same effective dose with smaller or larger drug doses, respectively. All model simulations fall on the dashed line, where drug doses are equal: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e259" xlink:type="simple"/></inline-formula>. (B) Logistic growth model. As the population size, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e260" xlink:type="simple"/></inline-formula>, increases, competition causes the growth rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e261" xlink:type="simple"/></inline-formula>, to fall from its maximal value, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e262" xlink:type="simple"/></inline-formula>, to 0 at the carrying capacity, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e263" xlink:type="simple"/></inline-formula> (Eq. 4). Unless otherwise indicated, in model simulations <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e264" xlink:type="simple"/></inline-formula> at the outset of treatment (black circle).</p>
<p>(0.11 MB TIF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1000796.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.s002" xlink:type="simple"><label>Figure S2</label><caption>
<p>Prevention of resistance, and the synergy ceiling <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e265" xlink:type="simple"/></inline-formula>, are robust to changes in model parameters. To test the robustness of the model to parameter changes, we varied each parameter independently and measured its effect on both the relative ability of strongly synergistic and antagonistic drug pairs (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e266" xlink:type="simple"/></inline-formula>) to prevent multi-drug resistance, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e267" xlink:type="simple"/></inline-formula> (solid black line), and the level of the synergy ceiling <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e268" xlink:type="simple"/></inline-formula> (solid blue line). All lines have undergone 5-point smoothing. Dashed lines indicate the points at which synergistic and antagonistic drug pairs prevent resistance equally well (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e269" xlink:type="simple"/></inline-formula>, black), or the synergy ceiling is additive (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e270" xlink:type="simple"/></inline-formula>, blue). In each panel, those points corresponding to the original set of model parameters are indicated by circles. (A) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e271" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e272" xlink:type="simple"/></inline-formula> vary little with changes in drug dose <italic>D</italic>, (B) carrying capacity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e273" xlink:type="simple"/></inline-formula>, or (C) maximal growth rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e274" xlink:type="simple"/></inline-formula>. (D) As previously discussed, increases in the frequency of resistance mutations <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e275" xlink:type="simple"/></inline-formula> decrease <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e276" xlink:type="simple"/></inline-formula> substantially (<xref ref-type="fig" rid="pcbi-1000796-g003">Fig. 3</xref>), while having no significant effect on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e277" xlink:type="simple"/></inline-formula>. (E) Likewise, increases in the initial population size, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e278" xlink:type="simple"/></inline-formula>, significantly decrease <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e279" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1000796-g004">Fig. 4</xref>), but also decrease <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e280" xlink:type="simple"/></inline-formula>. (F) Changes in the Hill coefficient, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e281" xlink:type="simple"/></inline-formula>, of antibiotic killing had a more complex effect on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e282" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e283" xlink:type="simple"/></inline-formula>: while <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e284" xlink:type="simple"/></inline-formula> was consistently less than 1 over a wide range of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e285" xlink:type="simple"/></inline-formula> (antagonism better prevents resistance), its magnitude was parabolic with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e286" xlink:type="simple"/></inline-formula>, with antagonistic drug pairs having the greatest advantage for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e287" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e288" xlink:type="simple"/></inline-formula> also appeared parabolic with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e289" xlink:type="simple"/></inline-formula> and was lowest (most antagonistic) at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e290" xlink:type="simple"/></inline-formula>. In the limit of large <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e291" xlink:type="simple"/></inline-formula>, maximal antibiotic killing rates are achieved for both wild-type and single-drug resistant populations, regardless of drug interaction. Synergistic and antagonistic drug pairs therefore fail to differentially impact wild-type killing rates, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e292" xlink:type="simple"/></inline-formula> at high <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e293" xlink:type="simple"/></inline-formula> (black line). Furthermore, saturation of killing rates causes <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e294" xlink:type="simple"/></inline-formula> to be greater than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e295" xlink:type="simple"/></inline-formula> for all values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e296" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e297" xlink:type="simple"/></inline-formula> is therefore undefined for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e298" xlink:type="simple"/></inline-formula> (blue line), though saturation of the wild-type killing rate still causes efficacy to effectively plateau for low values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e299" xlink:type="simple"/></inline-formula>.</p>
<p>(0.37 MB TIF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1000796.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.s003" xlink:type="simple"><label>Figure S3</label><caption>
<p>Optimal drug interactions as a function of resistance frequency and initial population size. The contour map shows the synergy ceiling, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e300" xlink:type="simple"/></inline-formula>, for a given combination of resistance mutation frequency, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e301" xlink:type="simple"/></inline-formula>, and population size at the start of treatment, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e302" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e303" xlink:type="simple"/></inline-formula> decreases monotonically with increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e304" xlink:type="simple"/></inline-formula> (as in <xref ref-type="fig" rid="pcbi-1000796-g003">Fig. 3</xref>), but is nearly unaffected by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e305" xlink:type="simple"/></inline-formula>. The black line is a single contour above which antagonistic drug pairs prevent multi-drug resistance better than synergistic drug pairs (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e306" xlink:type="simple"/></inline-formula>). Above this contour, greater synergy increases the chance of multi-drug resistance; the optimal drug interaction must therefore fall below <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e307" xlink:type="simple"/></inline-formula>, with its specific value depending on the priority assigned to treatment efficacy versus prevention of multi-drug resistance. Below the contour, however (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e308" xlink:type="simple"/></inline-formula>), greater synergy decreases the chance of multi-drug resistance; the optimal drug interaction is therefore maximal synergy (region below the black contour is colored dark red), regardless of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e309" xlink:type="simple"/></inline-formula>. The magenta circle indicates the combination of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e310" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e311" xlink:type="simple"/></inline-formula> corresponding to the original set of model parameters.</p>
<p>(0.10 MB TIF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1000796.s004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.s004" xlink:type="simple"><label>Figure S4</label><caption>
<p>Partial antibiotic resistance weakens synergy ceiling behavior. In the model we assume strong antibiotic resistance, such that the antibiotic-resistant subpopulation feels the effect of only a single drug; effectively, this makes the MIC of the drug to which it is resistant infinite and produces the familiar synergy ceiling, in which efficacy increases with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e312" xlink:type="simple"/></inline-formula> up to a critical level <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e313" xlink:type="simple"/></inline-formula> and plateaus above it (blue line, <xref ref-type="fig" rid="pcbi-1000796-g002">Fig. 2</xref>; all lines have been shifted on the vertical axis for clarity). As previously discussed (<xref ref-type="fig" rid="pcbi-1000796-g003">Fig. 3</xref>), this plateau is due to the resistant subpopulation dying after the wild-type when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e314" xlink:type="simple"/></inline-formula>. When we weaken the assumption of strong resistance, however (MIC&lt;∞), drug interactions still affect drug-resistant mutants, even when such mutants are killed after the wild-type. This results in efficacy increasing over all <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e315" xlink:type="simple"/></inline-formula>, but retaining its characteristic biphasic profile (red, green, orange lines). This biphasic behavior is due to the stronger killing of the wild-type than the resistant mutant, which persists even with only partial resistance. While stronger resistance produces behavior similar to the typical synergy ceiling (MIC increases 100-fold, red line), weaker resistance (MIC increases 4-fold, orange line) yields a still-biphasic curve, but one in which increases in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000796.e316" xlink:type="simple"/></inline-formula> improve efficacy substantially in all cases. The synergy ceiling behavior is therefore most relevant in cases of strong antibiotic resistance.</p>
<p>(0.08 MB TIF)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1000796.s005" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.s005" xlink:type="simple"><label>Table S1</label><caption>
<p>Parameters used in this study.</p>
<p>(0.03 MB DOC)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1000796.s006" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000796.s006" xlink:type="simple"><label>Text S1</label><caption>
<p>(0.02 MB DOC)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>For helpful comments and discussion, we thank R. Jajoo, J.-B. Michel, R.C. Moellering, and R. Ward.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1000796-Levy1"><label>1</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Levy</surname><given-names>SB</given-names></name>
<name name-style="western"><surname>Marshall</surname><given-names>B</given-names></name>
</person-group>             <year>2004</year>             <article-title>Antibacterial resistance worldwide: causes, challenges and responses.</article-title>             <source>Nat Med</source>             <volume>10</volume>             <fpage>S122</fpage>             <lpage>S129</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Golan1"><label>2</label><element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="editor">
<name name-style="western"><surname>Golan</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Tashjian</surname><given-names>AH</given-names></name>
<name name-style="western"><surname>Armstrong</surname><given-names>EJ</given-names></name>
<name name-style="western"><surname>Armstrong</surname><given-names>AW</given-names></name>
</person-group>             <year>2005</year>             <source>Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy</source>             <publisher-loc>Philadelphia</publisher-loc>             <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>          </element-citation></ref>
<ref id="pcbi.1000796-Pillai1"><label>3</label><element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pillai</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Moellering</surname><given-names>RC</given-names></name>
<name name-style="western"><surname>Eliopoulos</surname><given-names>GM</given-names></name>
</person-group>             <year>2005</year>             <person-group person-group-type="editor">
<name name-style="western"><surname>Lorian</surname><given-names>V</given-names></name>
</person-group>             <source>Antibiotics in Laboratory Medicine</source>             <publisher-loc>Philadelphia</publisher-loc>             <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>             <fpage>365</fpage>             <lpage>440</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Rybak1"><label>4</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rybak</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>McGrath</surname><given-names>BJ</given-names></name>
</person-group>             <year>1996</year>             <article-title>Combination antimicrobial therapy for bacterial infections - Guidelines for the clinician.</article-title>             <source>Drugs</source>             <volume>52</volume>             <fpage>390</fpage>             <lpage>405</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Fitzgerald1"><label>5</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Fitzgerald</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Schoeberl</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Nielsen</surname><given-names>UB</given-names></name>
<name name-style="western"><surname>Sorger</surname><given-names>PK</given-names></name>
</person-group>             <year>2006</year>             <article-title>Systems biology and combination therapy in the quest for clinical efficacy.</article-title>             <source>Nat Chem Biol</source>             <volume>2</volume>             <fpage>458</fpage>             <lpage>466</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Loewe1"><label>6</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Loewe</surname><given-names>S</given-names></name>
</person-group>             <year>1953</year>             <article-title>The problem of synergism and antagonism of combined drugs.</article-title>             <source>Arzneimittel-Forschung-Drug Research</source>             <volume>3</volume>             <fpage>285</fpage>             <lpage>290</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Berenbaum1"><label>7</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Berenbaum</surname><given-names>MC</given-names></name>
</person-group>             <year>1989</year>             <article-title>What is synergy?</article-title>             <source>Pharmacol Rev</source>             <volume>41</volume>             <fpage>93</fpage>             <lpage>141</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Greco1"><label>8</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Greco</surname><given-names>WR</given-names></name>
<name name-style="western"><surname>Bravo</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Parsons</surname><given-names>JC</given-names></name>
</person-group>             <year>1995</year>             <article-title>The search for synergy - a critical review from a response-surface perspective.</article-title>             <source>Pharmacol Rev</source>             <volume>47</volume>             <fpage>331</fpage>             <lpage>385</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Keith1"><label>9</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Keith</surname><given-names>CT</given-names></name>
<name name-style="western"><surname>Borisy</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Stockwell</surname><given-names>BR</given-names></name>
</person-group>             <year>2005</year>             <article-title>Multicomponent therapeutics for networked systems.</article-title>             <source>Nat Rev Drug Discov</source>             <volume>4</volume>             <fpage>71</fpage>             <lpage>78</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Michel1"><label>10</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Michel</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Yeh</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Chait</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Moellering</surname><given-names>RC</given-names></name>
<name name-style="western"><surname>Kishony</surname><given-names>R</given-names></name>
</person-group>             <year>2008</year>             <article-title>Drug interactions modulate the potential for evolution of resistance.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>105</volume>             <fpage>14918</fpage>             <lpage>14923</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Hegreness1"><label>11</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Hegreness</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Shoresh</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Damian</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Hartl</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Kishony</surname><given-names>R</given-names></name>
</person-group>             <year>2008</year>             <article-title>Accelerated evolution of resistance in multidrug environments.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>105</volume>             <fpage>13977</fpage>             <lpage>13981</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Klein1"><label>12</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Klein</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Schorr</surname><given-names>SE</given-names></name>
</person-group>             <year>1953</year>             <article-title>The role of bacterial resistance in antibiotic synergism and antagonism.</article-title>             <source>J Bacteriol</source>             <volume>65</volume>             <fpage>454</fpage>             <lpage>465</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Chait1"><label>13</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Chait</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Craney</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kishony</surname><given-names>R</given-names></name>
</person-group>             <year>2007</year>             <article-title>Antibiotic interactions that select against resistance.</article-title>             <source>Nature</source>             <volume>446</volume>             <fpage>668</fpage>             <lpage>671</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Sanders1"><label>14</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Sanders</surname><given-names>CC</given-names></name>
<name name-style="western"><surname>Sanders</surname><given-names>WE</given-names></name>
<name name-style="western"><surname>Goering</surname><given-names>RV</given-names></name>
<name name-style="western"><surname>Werner</surname><given-names>V</given-names></name>
</person-group>             <year>1984</year>             <article-title>Selection of multiple antibiotic-resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>26</volume>             <fpage>797</fpage>             <lpage>801</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Mwangi1"><label>15</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Mwangi</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>SW</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>YJ</given-names></name>
<name name-style="western"><surname>Sieradzki</surname><given-names>K</given-names></name>
<name name-style="western"><surname>de Lencastre</surname><given-names>H</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>104</volume>             <fpage>9451</fpage>             <lpage>9456</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Cohen1"><label>16</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cohen</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>McMurry</surname><given-names>LM</given-names></name>
<name name-style="western"><surname>Hooper</surname><given-names>DC</given-names></name>
<name name-style="western"><surname>Wolfson</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Levy</surname><given-names>SB</given-names></name>
</person-group>             <year>1989</year>             <article-title>Cross-resistance to fluoroquinolones in Multiple-Antibiotic-Resistant (MAR) Escherichia coli selected by tetracycline or chloramphenicol - decreased drug accumulation associated with membrane changes in addition to OmpF reduction.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>33</volume>             <fpage>1318</fpage>             <lpage>1325</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Normark1"><label>17</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Normark</surname><given-names>BH</given-names></name>
<name name-style="western"><surname>Normark</surname><given-names>S</given-names></name>
</person-group>             <year>2002</year>             <article-title>Evolution and spread of antibiotic resistance.</article-title>             <source>J Intern Med</source>             <volume>252</volume>             <fpage>91</fpage>             <lpage>106</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Larder1"><label>18</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Larder</surname><given-names>BA</given-names></name>
<name name-style="western"><surname>Kemp</surname><given-names>SD</given-names></name>
</person-group>             <year>1989</year>             <article-title>Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT).</article-title>             <source>Science</source>             <volume>246</volume>             <fpage>1155</fpage>             <lpage>1158</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Handel1"><label>19</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Handel</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Regoes</surname><given-names>RR</given-names></name>
<name name-style="western"><surname>Antia</surname><given-names>R</given-names></name>
</person-group>             <year>2006</year>             <article-title>The Role of Compensatory Mutations in the Emergence of Drug Resistance.</article-title>             <source>PLoS Comput Biol</source>             <volume>2</volume>          </element-citation></ref>
<ref id="pcbi.1000796-Acar1"><label>20</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Acar</surname><given-names>JF</given-names></name>
</person-group>             <year>2000</year>             <article-title>Antibiotic synergy and antagonism.</article-title>             <source>Med Clin North Am</source>             <volume>84</volume>             <fpage>1391</fpage>             <lpage>1406</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Jumbe1"><label>21</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jumbe</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Louie</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Leary</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>WG</given-names></name>
<name name-style="western"><surname>Deziel</surname><given-names>MR</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.</article-title>             <source>J Clin Invest</source>             <volume>112</volume>             <fpage>275</fpage>             <lpage>285</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Craig1"><label>22</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Craig</surname><given-names>WA</given-names></name>
</person-group>             <year>1998</year>             <article-title>Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.</article-title>             <source>Clin Infect Dis</source>             <volume>26</volume>             <fpage>1</fpage>             <lpage>10; quiz 11–12</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Craig2"><label>23</label><element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Craig</surname><given-names>WA</given-names></name>
</person-group>             <source>Does the dose matter?; 2001</source>             <publisher-name>University of Chicago Press</publisher-name>             <fpage>S233</fpage>             <lpage>S237</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Eagle1"><label>24</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Eagle</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Fleischman</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Levy</surname><given-names>M</given-names></name>
</person-group>             <year>1953</year>             <article-title>“Continuous” vs. “discontinuous” therapy with penicillin; the effect of the interval between injections on therapeutic efficacy.</article-title>             <source>N Engl J Med</source>             <volume>248</volume>             <fpage>481</fpage>             <lpage>488</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Regoes1"><label>25</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Regoes</surname><given-names>RR</given-names></name>
<name name-style="western"><surname>Wiuff</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Zappala</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Garner</surname><given-names>KN</given-names></name>
<name name-style="western"><surname>Baquero</surname><given-names>F</given-names></name>
<etal/></person-group>             <year>2004</year>             <article-title>Pharmacodynamic functions: A multiparameter approach to the design of antibiotic treatment regimens.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>48</volume>             <fpage>3670</fpage>             <lpage>3676</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Smith1"><label>26</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Smith</surname><given-names>VH</given-names></name>
<name name-style="western"><surname>Holt</surname><given-names>RD</given-names></name>
</person-group>             <year>1996</year>             <article-title>Resource competition and within-host disease dynamics.</article-title>             <source>Trends Ecol Evol</source>             <volume>11</volume>             <fpage>386</fpage>             <lpage>389</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Lipsitch1"><label>27</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Dykes</surname><given-names>JK</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Ades</surname><given-names>EW</given-names></name>
<name name-style="western"><surname>King</surname><given-names>J</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model.</article-title>             <source>Vaccine</source>             <volume>18</volume>             <fpage>2895</fpage>             <lpage>2901</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-DallAntonia1"><label>28</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dall'Antonia</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Coen</surname><given-names>PG</given-names></name>
<name name-style="western"><surname>Wilks</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Whiley</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Millar</surname><given-names>M</given-names></name>
</person-group>             <year>2005</year>             <article-title>Competition between methicillin-sensitive and -resistant Staphylococcus aureus in the anterior nares.</article-title>             <source>J Hosp Infect</source>             <volume>61</volume>             <fpage>62</fpage>             <lpage>67</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Yeh1"><label>29</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Yeh</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Tschumi</surname><given-names>AI</given-names></name>
<name name-style="western"><surname>Kishony</surname><given-names>R</given-names></name>
</person-group>             <year>2006</year>             <article-title>Functional classification of drugs by properties of their pairwise interactions.</article-title>             <source>Nat Genet</source>             <volume>38</volume>             <fpage>489</fpage>             <lpage>494</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Yeh2"><label>30</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Yeh</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Hegreness</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Aiden</surname><given-names>AP</given-names></name>
<name name-style="western"><surname>Kishony</surname><given-names>R</given-names></name>
</person-group>             <year>2009</year>             <article-title>Drug interactions and the evolution of antibiotic resistance.</article-title>             <source>Nat Rev Microbiol</source>             <volume>7</volume>             <fpage>460</fpage>             <lpage>466</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Freter1"><label>31</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Freter</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Brickner</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Botney</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Cleven</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Aranki</surname><given-names>A</given-names></name>
</person-group>             <year>1983</year>             <article-title>Mechanisms that control bacterial populations in continuous-flow culture models of mouse large intestinal flora.</article-title>             <source>Infect Immun</source>             <volume>39</volume>             <fpage>676</fpage>             <lpage>685</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Weinberg1"><label>32</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Weinberg</surname><given-names>ED</given-names></name>
<name name-style="western"><surname>Weinberg</surname><given-names>GA</given-names></name>
</person-group>             <year>1995</year>             <article-title>The role of iron in infection.</article-title>             <source>Curr Opin Infect Dis</source>             <volume>8</volume>             <fpage>164</fpage>             <lpage>169</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Nadell1"><label>33</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Nadell</surname><given-names>CD</given-names></name>
<name name-style="western"><surname>Xavier</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Levin</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Foster</surname><given-names>KR</given-names></name>
</person-group>             <year>2008</year>             <article-title>The evolution of quorum sensing in bacterial biofilms.</article-title>             <source>PLoS Biol</source>             <volume>6</volume>             <fpage>171</fpage>             <lpage>179</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Zhang1"><label>34</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>TC</given-names></name>
<name name-style="western"><surname>Fu</surname><given-names>YC</given-names></name>
<name name-style="western"><surname>Bishop</surname><given-names>PL</given-names></name>
</person-group>             <year>1995</year>             <article-title>Competition for substrate and space in biofilms.</article-title>             <source>Water Environ Res</source>             <volume>67</volume>             <fpage>992</fpage>             <lpage>1003</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Martinez1"><label>35</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Martinez</surname><given-names>JL</given-names></name>
<name name-style="western"><surname>Baquero</surname><given-names>F</given-names></name>
</person-group>             <year>2000</year>             <article-title>Mutation frequencies and antibiotic resistance.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>44</volume>             <fpage>1771</fpage>             <lpage>1777</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Tucker1"><label>36</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tucker</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Stiebel</surname><given-names>TR</given-names></name>
<name name-style="western"><surname>Potts</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Smidt</surname><given-names>ML</given-names></name>
<name name-style="western"><surname>Bryant</surname><given-names>ML</given-names></name>
</person-group>             <year>1998</year>             <article-title>Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>42</volume>             <fpage>478</fpage>             <lpage>480</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Meletiadis1"><label>37</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Meletiadis</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Stergiopoulou</surname><given-names>T</given-names></name>
<name name-style="western"><surname>O'Shaughnessy</surname><given-names>EM</given-names></name>
<name name-style="western"><surname>Peter</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Walsh</surname><given-names>TJ</given-names></name>
</person-group>             <year>2007</year>             <article-title>Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: Analysis by a new response surface model.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>51</volume>             <fpage>2053</fpage>             <lpage>2064</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Rand1"><label>38</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rand</surname><given-names>KH</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>P</given-names></name>
</person-group>             <year>1995</year>             <article-title>Concentration-dependent synergy and antagonism between cefoperazone and imipenem against methicillin-resistant Staphylococcus aureus.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>39</volume>             <fpage>1173</fpage>             <lpage>1177</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Lipsitch2"><label>39</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Levin</surname><given-names>BR</given-names></name>
</person-group>             <year>1997</year>             <article-title>The population dynamics of antimicrobial chemotherapy.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>41</volume>             <fpage>363</fpage>             <lpage>373</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Roberts1"><label>40</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Roberts</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Kruger</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Paterson</surname><given-names>DL</given-names></name>
<name name-style="western"><surname>Lipman</surname><given-names>J</given-names></name>
</person-group>             <year>2008</year>             <article-title>Antibiotic resistance - What's dosing got to do with it?</article-title>             <source>Crit Care Med</source>             <volume>36</volume>             <fpage>2433</fpage>             <lpage>2440</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Knudsen1"><label>41</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Knudsen</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Odenholt</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Erlendsdottir</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Gottfredsson</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Cars</surname><given-names>O</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>47</volume>             <fpage>2499</fpage>             <lpage>2506</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Foo1"><label>42</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Foo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Michor</surname><given-names>F</given-names></name>
</person-group>             <year>2009</year>             <article-title>Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies.</article-title>             <source>PLoS Comput Biol</source>             <volume>5</volume>          </element-citation></ref>
<ref id="pcbi.1000796-Grant1"><label>43</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Grant</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Restif</surname><given-names>O</given-names></name>
<name name-style="western"><surname>McKinley</surname><given-names>TJ</given-names></name>
<name name-style="western"><surname>Sheppard</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Maskell</surname><given-names>DJ</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Modelling within-host spatiotemporal dynamics of invasive bacterial disease.</article-title>             <source>PLoS Biol</source>             <volume>6</volume>             <fpage>757</fpage>             <lpage>770</lpage>          </element-citation></ref>
<ref id="pcbi.1000796-Wodarz1"><label>44</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wodarz</surname><given-names>D</given-names></name>
</person-group>             <year>2006</year>             <article-title>Ecological and evolutionary principles in immunology.</article-title>             <source>Ecol Lett</source>             <volume>9</volume>             <fpage>694</fpage>             <lpage>705</lpage>          </element-citation></ref>
</ref-list>

</back>
</article>